Abstract
COVID-19 is the current day pandemic that has claimed around 1,054,604 lives globally till date. Moreover, the number of deaths is going to increase over the next few months until the pandemic comes to an end, and a second wave has also been reported in few countries. Most interestingly, the death rate among certain populations from the same COVID-19 infection is highly variable. For instance, the European populations show a very high death rate, in contrast to the populations from Chinese ethnicities. Amongst all the closed cases with an outcome (total recovered + total died), the death rate in Italy is 13%, Iran is 6%, China is 5%, Brazil is 3%, The United States of America is 2%, India 2%, Israel is 1% as of October 08, 2020. However, the percentage was higher during the early phase of the pandemic. Moreover, the global death rate amongst all the patients with an outcome is 4%. Here we have reviewed virus-transmitted various respiratory tract infections and postulated a better understanding of SARS-CoV2 using lung stem cell organoids in vitro. Hence, here we propose the strategies of understanding first the infectivity/severity ratio of COVID-19 infections using various ethnicity originated induced pluripotent stem cell-derived lung stem cell organoids in vitro. The greater the infectivity to severity ratio, the better the disease outcome with the value of 1 being the worst disease outcome. This strategy will be useful for understanding the infectivity/severity ratio of virus induced respiratory tract infections for a possible betterment of community-based disease management. Also, such a strategy will be useful for screening the effect of various antiviral drugs/repurposed drugs for their efficacy in vitro.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agostini ML, Andres EL, Sims AC et al (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9(2):e00221-18. https://doi.org/10.1128/mBio.00221-18
Alvarez AE, Marson FA, Bertuzzo CS, Arns CW, Ribeiro JD (2013) Epidemiological and genetic characteristics associated with the severity of acute viral bronchiolitis by respiratory syncytial virus. J Pediatr 89(6):531–543. https://doi.org/10.1016/j.jped.2013.02.022
Amirian ES, Levy JK (2020) Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health 9:100128. https://doi.org/10.1016/j.onehlt.2020.100128
Arabi YM, Alothman A, Balkhy HH et al (2018) Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 19(1):81. https://doi.org/10.1186/s13063-017-2427-0
Cao B, Wang Y, Wen D et al (2020) A trial of Lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382(19):1787–1799. https://doi.org/10.1056/NEJMoa2001282
Chan JF, Chan KH, Choi GK et al (2013) Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 207(11):1743–1752. https://doi.org/10.1093/infdis/jit123
Chen Q, Tang K, Zhang X, Chen P, Guo Y (2018) Establishment of pseudovirus infection mouse models for in vivo pharmacodynamics evaluation of filovirus entry inhibitors. Acta Pharm Sin B 8(2):200–208. https://doi.org/10.1016/j.apsb.2017.08.003
Crawford D, Dearmun A (2017) Joubert syndrome. Nurs Child Young People 29(5):15. https://doi.org/10.7748/ncyp.29.5.15.s19
Datta I, Sowmithra, Jagtap S, Potdar C, Yadav R, Pal P (2020) Generation of induced pluripotent stem cells (NIMHi001-A) from a Parkinson’s disease patient of East Indian ethnicity carrying LRRK2 I1371V variant. Stem Cell Res 44:101768. https://doi.org/10.1016/j.scr.2020.101768
De Sousa PA, Steeg R, Wachter E et al (2017) Rapid establishment of the European Bank for induced pluripotent stem cells (EBiSC) – the hot start experience. Stem Cell Res 20:105–114. https://doi.org/10.1016/j.scr.2017.03.002
de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016) SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14(8):523–534. https://doi.org/10.1038/nrmicro.2016.81
Dye BR, Hill DR, Ferguson MA et al (2015) In vitro generation of human pluripotent stem cell derived lung organoids. elife 4:e05098. https://doi.org/10.7554/eLife.05098
Dye BR, Youngblood RL, Oakes RS et al (2020) Human lung organoids develop into adult airway-like structures directed by physico-chemical biomaterial properties. Biomaterials 234:119757. https://doi.org/10.1016/j.biomaterials.2020.119757
Fantini J, Di Scala C, Chahinian H, Yahi N (2020) Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents 105960. https://doi.org/10.1016/j.ijantimicag.2020.105960
Firth AL, Dargitz CT, Qualls SJ et al (2014) Generation of multiciliated cells in functional airway epithelia from human induced pluripotent stem cells. Proc Natl Acad Sci U S A 111(17):E1723–E1730. https://doi.org/10.1073/pnas.1403470111
Gautret P, Lagier JC, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print, 2020 Mar 20]. Int J Antimicrob Agents:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
George CC (2018) The European Bank for Induced Pluripotent Stem Cells (EBiSC): opportunities & challenges through public-private collaboration. Studia Iuridica 73:29–41
Grein J, Ohmagari N, Shin D et al (2020) Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med:NEJMoa2007016. https://doi.org/10.1056/NEJMoa2007016
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res 7(1):11. https://doi.org/10.1186/s40779-020-00240-0
Hall CB (2001) Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344(25):1917–1928. https://doi.org/10.1056/NEJM200106213442507
Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052
Kadzik RS, Morrisey EE (2012) Directing lung endoderm differentiation in pluripotent stem cells. Cell Stem Cell 10(4):355–361. https://doi.org/10.1016/j.stem.2012.03.013
Kaye M (2006) SARS-associated coronavirus replication in cell lines. Emerg Infect Dis 12(1):128–133. https://doi.org/10.3201/eid1201.050496
Leader S, Kohlhase K (2002) Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 21(7):629–632. https://doi.org/10.1097/00006454-200207000-00005
Longmire TA, Ikonomou L, Hawkins F et al (2012) Efficient derivation of purified lung and thyroid progenitors from embryonic stem cells. Cell Stem Cell 10(4):398–411. https://doi.org/10.1016/j.stem.2012.01.019
Lu H (2020) Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 14(1):69–71. https://doi.org/10.5582/bst.2020.01020
Lukassen S, Chua RL, Trefzer T et al (2020) SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J 39(10):e105114. https://doi.org/10.15252/embj.20105114
McMichael AJ (2004) Environmental and social influences on emerging infectious diseases: past, present and future. Philos Trans R Soc Lond Ser B Biol Sci 359(1447):1049–1058. https://doi.org/10.1098/rstb.2004.1480
Openshaw PJ, Tregoning JS (2005) Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 18(3):541–555. https://doi.org/10.1128/CMR.18.3.541-555.2005
Park AW (2019) Phylogenetic aggregation increases zoonotic potential of mammalian viruses. Biol Lett 15(12):20190668. https://doi.org/10.1098/rsbl.2019.0668
Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D (2020) Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis:S1473-3099(20)30198-5. https://doi.org/10.1016/S1473-3099(20)30198-5
Rosati J, Altieri F, Tardivo S et al (2018a) Production and characterization of human induced pluripotent stem cells (iPSCs) from Joubert Syndrome: CSSi001-A (2850). Stem Cell Res 27:74–77. https://doi.org/10.1016/j.scr.2018.01.012
Rosati J, Ferrari D, Altieri F et al (2018b) Establishment of stable iPS-derived human neural stem cell lines suitable for cell therapies. Cell Death Dis 9(10):937. https://doi.org/10.1038/s41419-018-0990-2
Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W (2020) Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol 38(1):10–18. https://doi.org/10.12932/AP-200220-0773
Tahamtan A, Samadizadeh S, Rastegar M, Nakstad B, Salimi V (2020) Respiratory syncytial virus infection: why does disease severity vary among individuals? Expert Rev Respir Med 14(4):415–423. https://doi.org/10.1080/17476348.2020.1724095
Tseng CT, Perrone LA, Zhu H, Makino S, Peters CJ (2005) Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J Immunol 174(12):7977–7985. https://doi.org/10.4049/jimmunol.174.12.7977
Turner M, Leslie S, Martin NG et al (2013) Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell 13(4):382–384. https://doi.org/10.1016/j.stem.2013.08.003
Vijaykrishna D, Smith GJ, Zhang JX, Peiris JS, Chen H, Guan Y (2007) Evolutionary insights into the ecology of coronaviruses. J Virol 81(8):4012–4020. https://doi.org/10.1128/JVI.02605-06
Wang M, Cao R, Zhang L et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269–271. https://doi.org/10.1038/s41422-020-0282-0
Wong ACP, Li X, Lau SKP, Woo PCY (2019) Global epidemiology of bat coronaviruses. Viruses 11(2):174. https://doi.org/10.3390/v11020174
Wu F, Zhao S, Yu B et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579(7798):265–269. https://doi.org/10.1038/s41586-020-2008-3
Yang YL, Qin P, Wang B et al (2019) Broad cross-species infection of cultured cells by bat HKU2-related swine acute diarrhea syndrome coronavirus and identification of its replication in murine dendritic cells in vivo highlight its potential for diverse interspecies transmission. J Virol 93(24):e01448–e01419. https://doi.org/10.1128/JVI.01448-19
Zhang T, Wu Q, Zhang Z (2020a) Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol 30(7):1346–1351.e2. https://doi.org/10.1016/j.cub.2020.03.022
Zhang B, Liu S, Tan T et al (2020b) Treatment with convalescent plasma for critically Ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest:S0012-3692(20)30571-7. https://doi.org/10.1016/j.chest.2020.03.039
Zhou P, Yang XL, Wang XG et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273. https://doi.org/10.1038/s41586-020-2012-7
Acknowledgements
The authors would like to thank Dr. Debprasad Chattopadhyay, Virologist from the Indian Council of Medical Research and Director, National Institute of Traditional Medicine, Belagavi, Karnataka, India regarding discussions for understanding various aspects of the SARS-CoV2. Authors deeply thank Dr. Mangesh Suryavanshi, National Post-Doctoral Fellow working in the Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka for his voluntary initiative with the latest literature regarding SARS-CoV2. Dr. Ranajit Das, a population geneticist and Assistant Professor, Yenepoya Research Centre, Yenepoya (Deemed to be University) is also acknowledged for his insights regarding various human ethnic groups and possible difference in infectivity/severity of SARS-CoV2. Finally, the authors thank the stringent COVID-19 lockdown situation which made strong reasons for writing this hypothesis and commentary article. No funding was utilized for preparing this manuscript.
Author’s Contributions
BB conceptualized, designed and wrote the manuscript; designed the figures and approved the manuscript. SK and MN edited the manuscript and made the figures.
Conflict of Interest
The authors declare no potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bose, B., Kapoor, S., Nihad, M. (2020). Induced Pluripotent Stem Cell Derived Human Lung Organoids to Map and Treat the SARS-CoV2 Infections In Vitro. In: Turksen, K. (eds) Cell Biology and Translational Medicine, Volume 11. Advances in Experimental Medicine and Biology(), vol 1312. Springer, Cham. https://doi.org/10.1007/5584_2020_613
Download citation
DOI: https://doi.org/10.1007/5584_2020_613
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71924-1
Online ISBN: 978-3-030-71925-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)